N-methylpiperidine-4-carboxamide → HCID 44545153, compound

HRID 2093397Notes

Reaction equation

HRID 2093397 reaction equation
C(OC([NH:8][C:9]1[N:14]=[CH:13][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][CH2:25][C:26](O)=[O:27])=[C:17]([N:29]3[CH2:34][CH2:33][O:32][CH2:31][CH2:30]3)[N:16]=2)=[CH:11][N:10]=1)=O)(C)(C)C.[CH3:35][NH:36][C:37]([CH:39]1[CH2:44][CH2:43][NH:42][CH2:41][CH2:40]1)=[O:38]>>[NH2:8][C:9]1[N:10]=[CH:11][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][CH2:25][C:26]([N:42]3[CH2:43][CH2:44][CH:39]([C:37]([NH:36][CH3:35])=[O:38])[CH2:40][CH2:41]3)=[O:27])=[C:17]([N:29]3[CH2:34][CH2:33][O:32][CH2:31][CH2:30]3)[N:16]=2)=[CH:13][N:14]=1

Participants

3

Reactant 2

HCID 2760460N-methylpiperidine-4-carboxamideHCID 66909826HCID 66909826, compound

Product 1

HCID 44545153HCID 44545153, compound

Procedure

3-(2-(2-(Tert-butoxycarbonylamino)pyrimidin-5-yl)-6-morpholino-9H-purin-9-yl)propanoic acid (50 mg) was reacted with N-methylpiperidine-4-carboxamide via General Procedure F followed by Boc deprotection via General Procedure E to give 10.9 mg 111 as white solid following reverse phase purification. MS (Q1) 495.3 (M)+

Workup

  1. customto give
  2. custom10.9 mg 111 as white solid following reverse phase purification

Sources & evidence

ORD record
ord-68da0c17b4964bb7a979cde855a00407
Source dataset
uspto-grants-2013_05
Patent number
US08445487B2

Reaction notes

Loading…